A newly identified COVID-19 variant, known as BA.3.2 and informally dubbed the “Cicada” variant, has raised fresh concerns among global health experts due to its unusually high number of mutations. Scientists report that the variant carries nearly 70-75 mutations in its spike protein significantly higher than many previous strains prompting close monitoring worldwide.
The BA.3.2 variant is part of the Omicron lineage of the SARS-CoV-2 virus and was first detected in South Africa in November 2024. Experts note that the large number of mutations especially in the spike protein, which helps the virus enter human cells could potentially enhance transmissibility and allow the virus to partially evade immunity from vaccines or prior infections. The variant has now been detected in over 20 countries including parts of Europe and the United States, where it has been identified through clinical samples, travelers and wastewater surveillance. In some regions of Europe, it has accounted for a notable share of cases indicating its ability to spread internationally.
Preliminary studies suggest that the variant shows signs of “immune escape,” meaning it may partially reduce the effectiveness of antibodies generated through vaccination or previous infection. However, health experts emphasize that existing vaccines are still expected to provide protection against severe illness and hospitalization. Despite its high mutation count, the symptoms associated with the new variant appear largely similar to earlier COVID-19 strains. Common symptoms include sore throat, fever, cough, fatigue and congestion. Most reported cases so far have been mild to moderate with no clear evidence yet of increased severity.
Public health authorities have advised people to remain cautious but not alarmed. Experts stress the importance of continued surveillance, vaccination and basic preventive measures such as hygiene and mask use in high-risk settings. They also highlight that the virus continues to evolve making monitoring and preparedness essential. The emergence of the BA.3.2 “Cicada” variant underscores the ongoing evolution of COVID-19 and the need for sustained vigilance. While the high number of mutations has raised concerns about transmission and immune escape, current evidence suggests that the situation remains under control with no immediate cause for panic.